NV-387 Shows Promising Antiviral Properties with Sustained Blood Concentration

NanoViricides, Inc., a clinical-stage company specializing in broad-spectrum antiviral nanomedicines, announced encouraging results for its lead candidate, NV-387. This drug demonstrated an ideal flat blood concentration profile in animal models, sustaining antiviral effects for a longer duration.

When administered orally, NV-387 achieved a peak blood concentration within the first hour, remaining nearly constant for eight hours before declining to baseline after twelve hours. Similar results were observed in both rats and dogs.

A six-dose regimen extended this plateau to 24 hours after repeated dosing. Importantly, this profile was consistent across both species and genders, suggesting potential for infrequent dosing without unwanted side effects.

The company believes NV-387 could revolutionize the treatment of respiratory viral infections such as RSV, COVID-19, and Influenza. Previous studies have shown NV-387 to be superior to existing therapeutics in preclinical trials.

NV-387 has completed Phase I human clinical safety trials with no reported adverse events, paving the way for Phase II clinical trials.